LGALS16

Across TCGA pan-cancer cohorts, LGALS16 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated LGALS16 data layer compared with 14 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher LGALS16 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LGALS16 expression acts as an unfavorable survival marker.

SKCM are the cancer types where LGALS16 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	II,III,IV	0.192	0.691	.032	6	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

LGALS16–SKCM (DFS)

Open the SKCM breakdown →